JP2013507416A - Mdm2−p53相互作用の阻害剤として新規なn−置換ピロリジン - Google Patents

Mdm2−p53相互作用の阻害剤として新規なn−置換ピロリジン Download PDF

Info

Publication number
JP2013507416A
JP2013507416A JP2012533592A JP2012533592A JP2013507416A JP 2013507416 A JP2013507416 A JP 2013507416A JP 2012533592 A JP2012533592 A JP 2012533592A JP 2012533592 A JP2012533592 A JP 2012533592A JP 2013507416 A JP2013507416 A JP 2013507416A
Authority
JP
Japan
Prior art keywords
phenyl
chloro
fluoro
coch
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012533592A
Other languages
English (en)
Japanese (ja)
Inventor
デイビッド ジョゼフ バートコビッツ,
シン−チー チュー,
チン−ジュン リュー,
ティナ モーガン ロス,
ジュミン チャン,
Original Assignee
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト filed Critical エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト
Publication of JP2013507416A publication Critical patent/JP2013507416A/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2012533592A 2009-10-14 2010-10-11 Mdm2−p53相互作用の阻害剤として新規なn−置換ピロリジン Pending JP2013507416A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25141309P 2009-10-14 2009-10-14
US61/251,413 2009-10-14
US34562610P 2010-05-18 2010-05-18
US61/345,626 2010-05-18
PCT/EP2010/065159 WO2011045257A1 (en) 2009-10-14 2010-10-11 Novel n-substituted-pyrrolidines as inhibitors of mdm2-p-53 interactions

Publications (1)

Publication Number Publication Date
JP2013507416A true JP2013507416A (ja) 2013-03-04

Family

ID=43567698

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012533592A Pending JP2013507416A (ja) 2009-10-14 2010-10-11 Mdm2−p53相互作用の阻害剤として新規なn−置換ピロリジン

Country Status (12)

Country Link
US (1) US8017607B2 (OSRAM)
EP (1) EP2488491A1 (OSRAM)
JP (1) JP2013507416A (OSRAM)
KR (1) KR20120081210A (OSRAM)
CN (1) CN102548963A (OSRAM)
AU (1) AU2010305914A1 (OSRAM)
BR (1) BR112012008485A2 (OSRAM)
CA (1) CA2774512A1 (OSRAM)
IL (1) IL218018A0 (OSRAM)
IN (1) IN2012DN02487A (OSRAM)
MX (1) MX2012003982A (OSRAM)
WO (1) WO2011045257A1 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
US8592377B2 (en) 2007-03-28 2013-11-26 President And Fellows Of Harvard College Stitched polypeptides
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
US20110118283A1 (en) * 2009-11-17 2011-05-19 Qingjie Ding Substituted Pyrrolidine-2-Carboxamides
WO2012021876A2 (en) 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2012076513A1 (en) * 2010-12-09 2012-06-14 F. Hoffmann-La Roche Ag 3-cyano-1-hydroxymethyl-2-phenylpyrrolidine derivatives as inhibitors of mdm2-p53 interactions useful for the treatment of cancer
SG193002A1 (en) 2011-03-10 2013-09-30 Daiichi Sankyo Co Ltd Dispiropyrrolidine derivative
CN108929375A (zh) 2011-10-18 2018-12-04 爱勒让治疗公司 拟肽大环化合物
WO2013123267A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
RU2642299C2 (ru) 2012-02-15 2018-01-24 Эйлерон Терапьютикс, Инк. P53 пептидомиметические макроциклы
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
US9604919B2 (en) 2012-11-01 2017-03-28 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
BR112015013611A2 (pt) 2012-12-20 2017-11-14 Merck Sharp & Dohme composto, e, composição farmacêutica
AU2015320545C1 (en) 2014-09-24 2020-05-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
KR20170058424A (ko) 2014-09-24 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
MX2017011834A (es) 2015-03-20 2018-04-11 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
EP3347372A4 (en) 2015-09-10 2019-09-04 Aileron Therapeutics, Inc. PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0947511A1 (en) 1998-03-30 1999-10-06 F. Hoffmann-La Roche Ag Derivatives of phenoxy acetic acid and of phenoxymethyl tetrazole having antitumor activity
SK822002A3 (en) 1999-07-21 2002-09-10 Astrazeneca Ab New compounds
WO2005099687A2 (en) 2004-04-09 2005-10-27 President And Fellows Of Harvard College Analogs of salinosporamide a
US7423051B2 (en) 2004-07-15 2008-09-09 Hoffmann-La Roche Inc. 2,6-diaminopyridine derivatives
MX2007010272A (es) 2005-02-22 2008-03-12 Univ Michigan Inhibidores de moleculas pequenas de mdm2 y usos de los mismos.
AU2007207052B2 (en) 2006-01-18 2012-07-12 F. Hoffmann-La Roche Ag CIS-4, 5-biaryl-2-heterocyclic-imidazolines as MDM2 inhibitors
KR20090042779A (ko) 2006-06-30 2009-04-30 쉐링 코포레이션 P53 활성을 증가시키는 치환된 피페리딘 및 이의 사용
MY160424A (en) 2008-09-18 2017-03-15 Hoffmann La Roche Substituted pyrrolidine-2-carboxyamides.

Also Published As

Publication number Publication date
IN2012DN02487A (OSRAM) 2015-08-28
IL218018A0 (en) 2012-04-30
US20110086854A1 (en) 2011-04-14
BR112012008485A2 (pt) 2019-09-24
MX2012003982A (es) 2012-05-08
CA2774512A1 (en) 2011-04-21
US8017607B2 (en) 2011-09-13
KR20120081210A (ko) 2012-07-18
EP2488491A1 (en) 2012-08-22
AU2010305914A1 (en) 2012-03-08
WO2011045257A1 (en) 2011-04-21
CN102548963A (zh) 2012-07-04

Similar Documents

Publication Publication Date Title
JP2013507416A (ja) Mdm2−p53相互作用の阻害剤として新規なn−置換ピロリジン
EP1603883B1 (en) Quinoline-derived amide modulators of vanilloid vr1 receptor
KR101714856B1 (ko) 치환된 피롤리딘-2-카복스아미드
RU2571100C2 (ru) Спироиндолинонпирролидины, полезные при лечении злокачественных новообразований
RU2442779C2 (ru) Производные 2,4,5-трифенилимидазолина как ингибиторы взаимодействия между белками p53 и mdm2, предназначенные для применения в качестве противораковых средств
US8058269B2 (en) Oxindole derivatives
US8288417B2 (en) N-substituted piperidines and their use as pharmaceuticals
JP4440642B2 (ja) ピリミジンA2b選択的アンタゴニスト化合物、それらの合成、及び使用
JP5405303B2 (ja) 置換されたスルホンアミド誘導体
JP6183451B2 (ja) 2−アシルアミノチアゾール誘導体またはその塩
JP4075064B2 (ja) 4,4−ジフルオロ−1,2,3,4−テトラヒドロ−5h−1−ベンゾアゼピン誘導体又はその塩
US20110118283A1 (en) Substituted Pyrrolidine-2-Carboxamides
JP2010527954A (ja) スピロインドリノン誘導体
EA014498B1 (ru) Производные бензамидов в качестве антагонистов брадикининовых рецепторов
WO2005063704A1 (ja) アゼチジン環化合物およびその医薬
JP2008523130A (ja) Crth2受容体アンタゴニスト活性を有するピロール誘導体
KR20060123415A (ko) 신규한 m3 무스카린성 아세틸콜린 수용체 길항제
JPH07233162A (ja) イミダゾリジノン誘導体とその酸付加塩及び老年性痴呆症の治療薬
JP2006506346A (ja) p38キナーゼ阻害剤としてのインドール系誘導体
CA2595936A1 (en) Substituted pyrazoles as modulators of chemokine receptors

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131217

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140520